{"title": "Hepatitis C treatment can be shortened in 50 percent of patients, study finds", "title_detail": {"type": "text/plain", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/personalized_medicine.xml", "value": "Hepatitis C treatment can be shortened in 50 percent of patients, study finds"}, "links": [{"rel": "alternate", "type": "text/html", "href": "https://www.sciencedaily.com/releases/2018/11/181112191704.htm"}], "link": "https://www.sciencedaily.com/releases/2018/11/181112191704.htm", "summary": "Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient. Findings from a new study could lead to significant cost savings. In 50 percent of patients, the standard 12-week treatment regimen could be shortened to as little as six weeks without compromising efficacy, the study found.", "summary_detail": {"type": "text/html", "language": null, "base": "https://www.sciencedaily.com/rss/health_medicine/personalized_medicine.xml", "value": "Hepatitis C drugs cure more than 90 percent of patients, but can cost more than $50,000 per patient. Findings from a new study could lead to significant cost savings. In 50 percent of patients, the standard 12-week treatment regimen could be shortened to as little as six weeks without compromising efficacy, the study found."}, "published": "Mon, 12 Nov 2018 19:17:04 EST", "published_parsed": [2018, 11, 13, 0, 17, 4, 1, 317, 0], "id": "https://www.sciencedaily.com/releases/2018/11/181112191704.htm", "guidislink": false}